Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial

The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.

Study Overview

• Status: Terminated
• Conditions: Arthritis, Rheumatoid
• Intervention / Treatment: Drug: BI 695500

• Study Type: Interventional
• Enrollment (Actual): 91
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Kortrijk, Belgium
    • 1301.4.0303 Boehringer Ingelheim Investigational Site
• Bulgaria
  • Plovdiv, Bulgaria
    • 1301.4.0609 Boehringer Ingelheim Investigational Site
• Germany
  • Magdeburg, Germany
    • 1301.4.1705 Boehringer Ingelheim Investigational Site
• Greece
  • Athens, Greece
    • 1301.4.1807 Boehringer Ingelheim Investigational Site
• Netherlands
  • Sneek, Netherlands
    • 1301.4.3305 Boehringer Ingelheim Investigational Site
• Poland
  • Bialystok, Poland
    • 1301.4.3909 Boehringer Ingelheim Investigational Site
  • Bydgoszcz, Poland
    • 1301.4.3907 Boehringer Ingelheim Investigational Site
  • Krakow, Poland
    • 1301.4.3915 Boehringer Ingelheim Investigational Site
  • Warszawa, Poland
    • 1301.4.3919 Boehringer Ingelheim Investigational Site
  • Wroclaw, Poland
    • 1301.4.3917 Boehringer Ingelheim Investigational Site
• Portugal
  • Amadora, Portugal
    • 1301.4.4013 Boehringer Ingelheim Investigational Site
  • Lisboa, Portugal
    • 1301.4.4007 Boehringer Ingelheim Investigational Site
• Spain
  • Sevilla, Spain
    • 1301.4.4809 Boehringer Ingelheim Investigational Site
  • Sevilla, Spain
    • 1301.4.4813 Boehringer Ingelheim Investigational Site
• United States
  • Alabama
    • Birmingham, Alabama, United States
      • 1301.4.5585 Boehringer Ingelheim Investigational Site
  • Arizona
    • Glendale, Arizona, United States
      • 1301.4.5727 Boehringer Ingelheim Investigational Site
    • Phoenix, Arizona, United States
      • 1301.4.5725 Boehringer Ingelheim Investigational Site
  • Arkansas
    • Little Rock, Arkansas, United States
      • 1301.4.5761 Boehringer Ingelheim Investigational Site
  • California
    • El Cajon, California, United States
      • 1301.4.5765 Boehringer Ingelheim Investigational Site
    • Lakewood, California, United States
      • 1301.4.5553 Boehringer Ingelheim Investigational Site
    • Long Beach, California, United States
      • 1301.4.5527 Boehringer Ingelheim Investigational Site
    • San Diego, California, United States
      • 1301.4.5771 Boehringer Ingelheim Investigational Site
    • Santa Maria, California, United States
      • 1301.4.5797 Boehringer Ingelheim Investigational Site
    • Upland, California, United States
      • 1301.4.5807 Boehringer Ingelheim Investigational Site
  • Florida
    • Pembroke Pines, Florida, United States
      • 1301.4.5809 Boehringer Ingelheim Investigational Site
    • Tampa, Florida, United States
      • 1301.4.5567 Boehringer Ingelheim Investigational Site
  • Illinois
    • Chicago, Illinois, United States
      • 1301.4.5561 Boehringer Ingelheim Investigational Site
  • Maryland
    • Columbia, Maryland, United States
      • 1301.4.5721 Boehringer Ingelheim Investigational Site
    • Cumberland, Maryland, United States
      • 1301.4.5811 Boehringer Ingelheim Investigational Site
  • Massachusetts
    • Worcester, Massachusetts, United States
      • 1301.4.5507 Boehringer Ingelheim Investigational Site
  • Michigan
    • Grand Rapids, Michigan, United States
      • 1301.4.5715 Boehringer Ingelheim Investigational Site
  • Nebraska
    • Omaha, Nebraska, United States
      • 1301.4.5787 Boehringer Ingelheim Investigational Site
  • New Jersey
    • Toms River, New Jersey, United States
      • 1301.4.5525 Boehringer Ingelheim Investigational Site
  • New York
    • Brooklyn, New York, United States
      • 1301.4.5779 Boehringer Ingelheim Investigational Site
  • North Carolina
    • Charlotte, North Carolina, United States
      • 1301.4.5717 Boehringer Ingelheim Investigational Site
  • Ohio
    • Dayton, Ohio, United States
      • 1301.4.5801 Boehringer Ingelheim Investigational Site
  • Tennessee
    • Memphis, Tennessee, United States
      • 1301.4.5549 Boehringer Ingelheim Investigational Site
    • Nashville, Tennessee, United States
      • 1301.4.5729 Boehringer Ingelheim Investigational Site
  • Texas
    • Carrollton, Texas, United States
      • 1301.4.5757 Boehringer Ingelheim Investigational Site
    • Corpus Christi, Texas, United States
      • 1301.4.5789 Boehringer Ingelheim Investigational Site
    • Houston, Texas, United States
      • 1301.4.5705 Boehringer Ingelheim Investigational Site
    • McKinney, Texas, United States
      • 1301.4.5597 Boehringer Ingelheim Investigational Site
  • West Virginia
    • Beckley, West Virginia, United States
      • 1301.4.5795 Boehringer Ingelheim Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 82 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

1. Must give written informed consent and be willing to follow this Clinical Trial Protocol.
2. Male or female patients, with moderately to severely active RA who have previously participated in the double-blind randomized clinical Trial 1301.1.

3. Current treatment for RA on an outpatient basis:

   1. Patients must continue to receive and tolerate oral or parenteral methotrexate (MTX) therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose).
   2. Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or folinic acid (at least 1 mg per week or as per local practice) or equivalent during the entire trial.
   3. If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.
   4. Intra-articular and parenteral corticosteroids are not permitted throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion as part of the trial procedures.
   5. Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable throughout the trial.
   6. Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day, or chloroquine provided that the dose is not greater than 250 mg/day. These doses must have been stable for a minimum of 12 weeks prior to Day 1. The hydroxychloroquine or chloroquine treatment will need to be continued at a stable dose with the same formulation until the end of the trial.
4. For participants of reproductive potential (males and females), use of a medically acceptable method of contraception during the trial, i.e., a combination of 2 forms of effective contraception (defined as hormonal contraception, intrauterine device, condom with spermicide, etc.). Females of childbearing potential must also agree to use an acceptable method of contraception (see above) for 12 months following completion or discontinuation from the trial medication.

Exclusion criteria:

1. Patients receiving current treatment with corticosteroids must not be receiving a dose exceeding 10 mg/day prednisone or equivalent.
2. Serious underlying medical conditions, which, per the investigator¿s discretion, could impair the ability of the patient to participate in the trial (including but not limited to ongoing severe infection, severe immunosuppression, severe heart failure, uncontrolled hypertension, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease).
3. Pregnancy or breast feeding. For women of childbearing potential, a positive serum pregnancy test at the Screening Visit.
4. Patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the New York Heart Association (NYHA) classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease; or uncontrolled hypertension.
5. Treatment with IV or intramuscular corticosteroids. The only exception will be the administration of 100 mg IV methylprednisolone 30 to 60 minutes before each infusion as part of the trial procedures.
6. Any condition or treatment (including biologic therapies) that, in the opinion of the investigator, may place the patient at unacceptable risk during the trial.
7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times upper limit of normal (ULN).
8. Hemoglobin <8.0 g/dL.
9. Levels of Immunoglobulin G(IgG) <5.0 g/L.
10. Absolute neutrophil count <1500/µL.
11. Platelet count <75000/µL.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: BI 695500; BI 695500, Two infusions separated by 2 weeks, Intravenous infusion	Drug: BI 695500

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Percentage of Patients With Drug Related Adverse Events During the Treatment Phase	This outcome measure presents percentage of patients with drug related adverse events during the treatment phase. Treatment Emergent Adverse Events (TEAEs) were defined as Adverse Events (AEs) that started or worsened in severity on or after the first dose of trial medication in this extension study [1301.4] and prior to the last date of trial medication + 180 days [inclusive]. Drug-related events were those considered by the investigator to have a causal relationship to trial medication.	Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Clinical Trial 1301.1 in Disease Activity Score 28 (DAS28) (Erythrocyte Sedimentation Rate [ESR]) at Week 48 of Clinical Trial 1301.4	DAS-28 (ESR)** is an index containing a 28-joint count for tenderness (TJC28), 28 joint count for swelling (SJC28), natural logarithm of ESR (inflammation) (Ln[ESR]) and a general health component (GH) which is the patient's global assessment of disease activity and was used to describe the severity of RA. The DAS28 (ESR) Score is calculated as: DAS28(ESR) = 0.56*√(TJC28) + 0.28*√(SJC28) + 0.70*ln(ESR) + 0.014*(GH). DAS28 values range from 2.0 to 10.0 while higher values mean a higher disease activity. A clinically important change in DAS28 score is defined as an improvement in DAS28 score of at least 1.2. The mean change from baseline (in clinical trial 1301.1) at Week 48 in the DAS28 (ESR) score is presented.	Baseline in clinical trial 1301.1 up to Week 48 in clinical trial 1301.4.
The Percentage of Patients Meeting the ACR20 [Based on Improvement Since Baseline in Trial 1301.1] at Week 48 of Trial 1301.4	A subject has an ACR20 response if all of the following occur: a > 20% improvement in the swollen joint count (66 joints); a > 20% improvement in the tender joint count (68 joints); a > 20% improvement in at least 3 of the following assessments: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function, as measured by the Health Assessment Questionnaire - Disability Index, or Acute phase reactant (CRP). The number of subjects meeting the ACR20 response criteria at Week 48 is presented.	Baseline in clinical trial 1301.1 up to Week 48 in clinical trial 1301.4.
The Percentage of Patients Who Meet the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Definition of Remission [Based on Improvement Since Baseline in Trial 1301.1] at Week 48 of Trial 1301.4	To meet the ACR/EULAR Remission criteria*, the subject needed to satisfy the following criteria: TCJ (68 joints) < 1; SJC (66 joints) < 1; CRP < 1 milligrams per decilitre; patient global assessment < 10. The patient global assessment for the definition of ACR/EULAR Remission was defined with a visual analog scale in millimetres (0-100).** The number of subjects meeting the ACR/EULAR Remission definition at Week 48 is presented.	Baseline in clinical trial 1301.1 up to Week 48 in clinical trial 1301.4.
The Percentage of Patients Who Meet the EULAR Response [Good Response, Moderate Response, or no Response] [Based on DAS28 Improvement Since Baseline in Trial 1301.1] at Week 48 of Trial 1301.4	This outcome measure presents percentage of patients who meet the EULAR response [good response, moderate response, or no response] [based on DAS28 improvement since baseline in trial 1301.1] at Week 48 of trial 1301.4.	Week 48

Collaborators and Investigators

• Sponsor: Boehringer Ingelheim

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 31, 2013
• Primary Completion (ACTUAL): November 18, 2015
• Study Completion (ACTUAL): November 7, 2016

Study Registration Dates

• First Submitted: September 30, 2013
• First Submitted That Met QC Criteria: October 4, 2013
• First Posted (ESTIMATE): October 7, 2013

Study Record Updates

• Last Update Posted (ACTUAL): January 18, 2018
• Last Update Submitted That Met QC Criteria: December 19, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: 1301.4; 2013-002622-23 (EUDRACT_NUMBER: EudraCT)